I-125 seeds with chemotherapy for progressive non-small-cell lung cancer after first-line treatment: a meta-analysis

Table 4 Meta-analytic results based on the studies regarding of different first-line treatments

	Number of studies	OR or HR (95% CI)	Heterogeneity	Favor
Concurrent chemoradiotherapy
CR	4	0.24 (0.13, 0.45), P < 0.0001	I² = 47%	Combined
TR	4	0.50 (0.33, 0.75), P = 0.001	I² = 0%	Combined
DC	4	0.31 (0.16, 0.62), P = 0.0008	I² = 0%	Combined
Myelosuppression	2	0.60 (0.36, 1.03), P = 0.06	I² = 0%	-
Gastrointestinal response	2	0.91 (0.55, 1.49), P = 0.70	I² = 0%	-
PFS	4	1.63 (1.32, 2.00), P < 0.00001	I² = 0%	Combined
OS	3	1.65 (1.33, 2.04), P < 0.00001	I² = 0%	Combined
Chemotherapy alone
CR	2	0.22 (0.09, 0.53), P = 0.0007	I² = 0%	Combined
TR	2	0.11 (0.06, 0.21), P < 0.00001	I² = 0%	Combined
DC	2	0.08 (0.02, 0.31), P = 0.002	I² = 46%	Combined
PFS	2	1.41 (0.83, 2.39), P = 0.20	I² = 87%	–
OS	2	1.34 (1.14, 1.57), P = 0.0004	I² = 39%	Combined

OR odd ratio, HR hazard ratio, CR complete response, TR treatment response, DC disease control, PFS progression-free survival, OS overall survival

ISSN: 1749-8090